FLT3 and acute myeloid leukemia: This result is consistent with the studies by Al-kali et al and Hu et al. The FLT3-ITD mutation is a well-known adverse prognostic factor in AML and the patients with the FLT3-ITD mutation had increased white blood cell counts, because it suppresses apoptosis and proliferates the dysregulated cells.[14–16] Despite the low frequency of the FLT3-ITD mutation in hypocellular AML patients, the prognosis is similar to that of non-hypocellular AML patients.